AQR Capital Management
DFTX

AQR Capital Management’s Definium Therapeutics DFTX Stock Holding History

AQR Capital Management’s Portfolio DFTX Stock Details DFTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$6.31M Buy
134,152
+77,058
+135% +$1.9M ﹤0.01% 1856
2026
Q1 		$1.08M Sell
57,094
-1,204
-2% -$20.4K ﹤0.01% 2722
2025
Q4 		$781K Buy
58,298
+36,702
+170% +$454K ﹤0.01% 2688
2025
Q3 		$255K Buy
21,596
+1,838
+9% +$17.1K ﹤0.01% 3158
2025
Q2 		$128K Buy
19,758
+7,508
+61% +$49.4K ﹤0.01% 3136
2025
Q1 		$71.7K Sell
12,250
-12,887
-51% -$92.3K ﹤0.01% 3061
2024
Q4 		$175K Buy
25,137
+2,364
+10% +$16.3K ﹤0.01% 2698
2024
Q3 		$130K Buy
+22,773
New +$158K ﹤0.01% 2628

Other funds holding DFTX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

AQR Capital Management's DFTX Position: Q2 2026 in Review

AQR Capital Management increased its Definium Therapeutics (DFTX) stake by 135% in Q2 2026, buying an estimated $1.9M and bringing the position to 134,152 shares worth $6.31M. The position accounts for ﹤0.01% of the portfolio, ranked #1856.

AQR Capital Management first reported a position in DFTX in Q3 2024 and has held it in 8 quarters since. 362 funds tracked by Wall St. Rank hold DFTX as of Q2 2026.

  • AQR Capital Management held 134,152 shares of Definium Therapeutics worth $6.31M as of Q2 2026.
  • AQR Capital Management bought 77,058 Definium Therapeutics shares in Q2 2026, an estimated $1.9M.
  • Definium Therapeutics made up ﹤0.01% of AQR Capital Management's portfolio in Q2 2026, its #1856 holding.
  • AQR Capital Management first reported a position in Definium Therapeutics in Q3 2024 and has held it in 8 quarters since.
  • 362 funds tracked by Wall St. Rank held Definium Therapeutics as of Q2 2026.

Based on AQR Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.